These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7818557)

  • 21. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis.
    Sunderkötter C; Riemekasten G
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii33-5. PubMed ID: 16987831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hand warming as a treatment for Raynaud's phenomenon in systemic sclerosis.
    Goodfield MJ; Rowell NR
    Br J Dermatol; 1988 Nov; 119(5):643-6. PubMed ID: 3207617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension.
    Wigley FM
    Curr Opin Rheumatol; 1996 Nov; 8(6):561-8. PubMed ID: 9018460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
    O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
    Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes.
    Clements PJ
    Curr Opin Rheumatol; 1994 Nov; 6(6):603-6. PubMed ID: 7865380
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of cold exposure on diffusing capacity in patients with Raynaud's phenomenon.
    Wise RA; Wigley F; Newball HH; Stevens MB
    Chest; 1982 Jun; 81(6):695-8. PubMed ID: 7075304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Raynaud's disease as a manifestation of organic changes in blood vessels in progressive scleroderma].
    Krull P; Wagner HH; Ostertag H; Deicher H
    Verh Dtsch Ges Rheumatol; 1972; 2():Suppl 2:130-3. PubMed ID: 5051940
    [No Abstract]   [Full Text] [Related]  

  • 29. Reproducibility of cold provocation in patients with Raynaud's phenomenon.
    Wigley FM; Malamet R; Wise RA
    J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pathogenic role for endothelin in Raynaud's phenomenon?
    Bottomley W; Goodfield M
    Acta Derm Venereol; 1994 Nov; 74(6):433-4. PubMed ID: 7701873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis.
    Shuck JW; Oetgen WJ; Tesar JT
    Am J Med; 1985 Feb; 78(2):221-7. PubMed ID: 3970048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the cold pressor test on diffusing capacity. Comparison of normal subjects and those with Raynaud's disease and progressive systemic sclerosis.
    Miller MJ
    Chest; 1983 Sep; 84(3):264-6. PubMed ID: 6884100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spontaneous neutrophil activation in patients with primary Raynaud's phenomenon and systemic sclerosis.
    Stevens TR; Hall ND; McHugh NJ; Maddison PJ
    Br J Rheumatol; 1992 Dec; 31(12):856. PubMed ID: 1458295
    [No Abstract]   [Full Text] [Related]  

  • 34. [Esophageal motor changes in patients with Raynaud's phenomenon and suspected scleroderma. Electromanometric and serologic evaluations].
    Benevento A; Barcellini W; Maestri L; Riva R; Sabbadini MG; Veralli E
    Minerva Med; 1984 Sep; 75(37):2111-8. PubMed ID: 6483266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The vasculopathy of Raynaud's phenomenon and scleroderma.
    Flavahan NA; Flavahan S; Mitra S; Chotani MA
    Rheum Dis Clin North Am; 2003 May; 29(2):275-91, vi. PubMed ID: 12841295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon.
    Zamora MR; O'Brien RF; Rutherford RB; Weil JV
    Lancet; 1990 Nov; 336(8724):1144-7. PubMed ID: 1978025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond Raynaud's phenomenon hides very early systemic sclerosis: the assessment of organ involvement is always mandatory.
    Czirják L; Matucci-Cerinic M
    Rheumatology (Oxford); 2011 Feb; 50(2):250-1. PubMed ID: 21115465
    [No Abstract]   [Full Text] [Related]  

  • 38. Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis.
    Herrick AL; Clark S
    Ann Rheum Dis; 1998 Feb; 57(2):70-8. PubMed ID: 9613334
    [No Abstract]   [Full Text] [Related]  

  • 39. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease.
    Cohen S; Fisher R; Lipshutz W; Turner R; Myers A; Schumacher R
    J Clin Invest; 1972 Oct; 51(10):2663-8. PubMed ID: 5056661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative assessment of the effects of vasodilators on peripheral vascular reactivity in patients with systemic scleroderma and Raynaud's phenomenon: color Doppler flow imaging study.
    Aikimbaev KS; Oğuz M; Ozbek S; Demirtaş M; Birand A; Batyraliev T
    Angiology; 1996 May; 47(5):475-80. PubMed ID: 8644944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.